|
WO2007001677A2
(en)
|
2005-05-17 |
2007-01-04 |
University Of Connecticut |
Compositions and methods for immunomodulation in an organism
|
|
JP5603012B2
(ja)
|
2005-12-02 |
2014-10-08 |
トヘ モウント シナイ スクール オフ メディシネ オフ ニューヨーク ウニベルシトイ |
非天然表面タンパク質を提示するキメラウイルス及びその使用
|
|
EP2366787B1
(en)
|
2006-01-13 |
2019-12-11 |
The Government Of The U.S.A, As Represented By The Secretary, Dept. Of Health And Human Services |
Codon optimized IL-15 and IL-15R-Alpha genes for expression in mammalian cells
|
|
EP2388266B1
(en)
|
2007-05-11 |
2014-04-23 |
Altor BioScience Corporation |
Fusion molecules and IL-15 variants
|
|
EP2173378B1
(en)
|
2007-06-27 |
2014-03-19 |
Admune Therapeutics LLC |
Complexes of il-15 and il-15ralpha and uses thereof
|
|
JP6251570B2
(ja)
|
2010-09-21 |
2017-12-20 |
アルター・バイオサイエンス・コーポレーション |
多量体ｉｌ−１５可溶性融合分子並びにその製造及び使用方法
|
|
US11053299B2
(en)
|
2010-09-21 |
2021-07-06 |
Immunity Bio, Inc. |
Superkine
|
|
WO2018112219A1
(en)
*
|
2016-12-14 |
2018-06-21 |
Nant Holdings Ip, Llc |
Superkine
|
|
EP3252076B1
(en)
|
2011-01-14 |
2019-09-04 |
The Regents Of The University Of California |
Diagnostic use of antibodies against ror-1 protein
|
|
US9156897B2
(en)
*
|
2012-06-08 |
2015-10-13 |
Alkermes, Inc. |
Fusion polypeptides comprising an active protein linked to a mucin-domain polypeptide
|
|
US20150359853A1
(en)
|
2012-10-24 |
2015-12-17 |
Admune Therapeutics Llc |
Il-15r alpha forms, cells expressing il-15r alpha forms, and therapeutic uses of il-15r alpha and il-15/il-15r alpha complexes
|
|
SG11201504558TA
(en)
*
|
2012-12-11 |
2015-07-30 |
Einstein Coll Med |
Methods for high throughput receptor:ligand identification
|
|
PE20151921A1
(es)
|
2013-03-14 |
2015-12-26 |
Icahn School Med Mount Sinai |
Virus de la enfermedad de newcastle y usos de los mismos
|
|
JP2016518361A
(ja)
|
2013-04-19 |
2016-06-23 |
シーチューヌ ファルマＣｙｔｕｎｅ Ｐｈａｒｍａ |
血管漏出症候群の発生を抑制するサイトカイン治療
|
|
EP2997134B1
(en)
*
|
2013-05-14 |
2020-06-24 |
Board of Regents, The University of Texas System |
Human application of engineered chimeric antigen receptor (car) t-cells
|
|
CA2920539C
(en)
*
|
2013-08-08 |
2024-01-02 |
Cytune Pharma |
Combined pharmaceutical composition
|
|
SI3030575T1
(sl)
*
|
2013-08-08 |
2018-11-30 |
Cytune Pharma |
Modulokini na osnovi IL-15 in IL-15R-alfa sushi domene
|
|
CA3191031A1
(en)
|
2013-09-27 |
2015-04-02 |
Massachusetts Institute Of Technology |
Carrier-free biologically-active protein nanostructures
|
|
EP3093295B1
(en)
*
|
2014-01-08 |
2020-05-27 |
Shanghai Hengrui Pharmaceutical Co., Ltd. |
Il-15 heterogeneous dimer protein and uses thereof
|
|
LT3094351T
(lt)
*
|
2014-01-15 |
2022-04-11 |
Kadmon Corporation, Llc |
Imunitetą moduliuojantys agentai
|
|
DK3105335T3
(da)
|
2014-02-14 |
2020-01-13 |
Univ Texas |
Kimære antigenreceptorer og fremgangsmåder til fremstilling heraf
|
|
AU2015222685A1
(en)
|
2014-02-27 |
2016-09-08 |
Viralytics Limited |
Combination method for treatment of cancer
|
|
EP2915569A1
(en)
*
|
2014-03-03 |
2015-09-09 |
Cytune Pharma |
IL-15/IL-15Ralpha based conjugates purification method
|
|
WO2015164107A1
(en)
|
2014-04-23 |
2015-10-29 |
Emory University |
Compositions of gm-csf and interleukin fusions for immune modulation and uses related thereto
|
|
EP3805371A1
(en)
|
2014-05-15 |
2021-04-14 |
National University of Singapore |
Modified natural killer cells and uses thereof
|
|
CA2953816C
(en)
|
2014-06-30 |
2022-03-15 |
Altor Bioscience Corporation |
Il-15-based molecules and methods of use thereof
|
|
US10335460B2
(en)
|
2014-07-29 |
2019-07-02 |
Novartis Ag |
IL-15 and IL-15Rα heterodimer dose escalation regimens for treating conditions
|
|
MA41044A
(fr)
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
|
|
SG11201702401RA
(en)
|
2014-10-14 |
2017-04-27 |
Novartis Ag |
Antibody molecules to pd-l1 and uses thereof
|
|
WO2016081601A1
(en)
*
|
2014-11-19 |
2016-05-26 |
Memorial Sloan-Kettering Cancer Center |
Methods and compositions for cancer treating conditions relating to over expressions of epha2
|
|
US10905743B2
(en)
*
|
2014-12-19 |
2021-02-02 |
Jiangsu Hengrui Medicine Co., Ltd. |
Interleukin 15 protein complex
|
|
CN104830884A
(zh)
*
|
2015-01-22 |
2015-08-12 |
苏州大学 |
一种携带IL-15/sIL-15Ra融合基因的微环DNA表达载体的构建方法
|
|
EP3064507A1
(en)
|
2015-03-06 |
2016-09-07 |
Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts |
Fusion proteins comprising a binding protein and an interleukin-15 polypeptide having a reduced affinity for IL15ra and therapeutic uses thereof
|
|
US12577323B2
(en)
|
2015-06-10 |
2026-03-17 |
Emory University |
Compositions and conjugates comprising an interleukin and polypeptides that specifically bind TGF-beta
|
|
CN112574316A
(zh)
*
|
2015-07-02 |
2021-03-30 |
博际生物医药科技(杭州)有限公司 |
用于肿瘤靶向治疗的白细胞介素-15融合蛋白
|
|
EP3328418A1
(en)
|
2015-07-29 |
2018-06-06 |
Novartis AG |
Combination therapies comprising antibody molecules to pd-1
|
|
US20180207273A1
(en)
|
2015-07-29 |
2018-07-26 |
Novartis Ag |
Combination therapies comprising antibody molecules to tim-3
|
|
US20180340025A1
(en)
|
2015-07-29 |
2018-11-29 |
Novartis Ag |
Combination therapies comprising antibody molecules to lag-3
|
|
AU2016305087B2
(en)
*
|
2015-08-12 |
2022-01-20 |
Massachusetts Institute Of Technology |
Cell surface coupling of nanoparticles
|
|
AU2016326575A1
(en)
*
|
2015-09-25 |
2018-04-12 |
Altor Bioscience Corporation |
Interleukin-15 superagonist significantly enhances graft-versus-tumor activity
|
|
JP7461620B2
(ja)
*
|
2015-10-06 |
2024-04-04 |
リージェンツ オブ ザ ユニバーシティ オブ ミネソタ |
治療用化合物及び方法
|
|
CN108495651A
(zh)
|
2015-12-17 |
2018-09-04 |
诺华股份有限公司 |
抗pd-1的抗体分子及其用途
|
|
AU2017219901B2
(en)
|
2016-02-19 |
2022-07-14 |
Nant Holdings Ip, Llc |
Methods of immunogenic modulation
|
|
SG11201808552XA
(en)
|
2016-05-18 |
2018-10-30 |
Cue Biopharma Inc |
T-cell modulatory multimeric polypeptides and methods of use thereof
|
|
IL262606B2
(en)
|
2016-05-18 |
2023-04-01 |
Albert Einstein College Medicine Inc |
pd-l1 variant polypeptides, T-cell modulatory multimeric polypeptides, and methods of using them
|
|
CA3024509A1
(en)
*
|
2016-05-18 |
2017-11-23 |
Modernatx, Inc. |
Mrna combination therapy for the treatment of cancer
|
|
EP3464352B1
(en)
*
|
2016-05-27 |
2021-03-24 |
Altor BioScience Corporation |
Construction and characterization of multimeric il-15-based molecules with cd3 binding domains
|
|
CN109715196A
(zh)
*
|
2016-06-13 |
2019-05-03 |
转矩医疗股份有限公司 |
用于促进免疫细胞功能的组合物和方法
|
|
WO2018011573A1
(en)
*
|
2016-07-12 |
2018-01-18 |
Kymab Limited |
Animals, cells, ligands, polypeptides & methods
|
|
WO2018058067A1
(en)
*
|
2016-09-23 |
2018-03-29 |
The Regents Of The University Of California |
Autologous irradiated whole cell tumor vaccines lentivirally engineered to express cd80, il-15 and il-15 receptor alpha
|
|
MX2019004327A
(es)
*
|
2016-10-14 |
2019-10-14 |
Xencor Inc |
Proteinas de fusion heterodimericas biespecificas que contienen proteinas de fusion fc il-15/il-15ra y fragmentos de anticuerpo pd-1.
|
|
JP7213180B2
(ja)
*
|
2016-10-19 |
2023-01-26 |
エフ．ホフマン－ラ ロシュ アーゲー |
免疫コンジュゲートを製造するための方法
|
|
MX2019004681A
(es)
*
|
2016-10-21 |
2019-10-07 |
Altor Bioscience Corp |
Moleculas basadas en il-15 multimericas.
|
|
CN110325205B
(zh)
|
2016-12-22 |
2023-08-15 |
库尔生物制药有限公司 |
T细胞调节性多聚体多肽及其使用方法
|
|
CN108250301A
(zh)
*
|
2016-12-29 |
2018-07-06 |
天津天锐生物科技有限公司 |
一种多靶点嵌合抗原受体
|
|
CN108250302A
(zh)
*
|
2016-12-29 |
2018-07-06 |
天津天锐生物科技有限公司 |
一种多功能蛋白质
|
|
US11851471B2
(en)
|
2017-01-09 |
2023-12-26 |
Cue Biopharma, Inc. |
T-cell modulatory multimeric polypeptides and methods of use thereof
|
|
EP3570869A1
(en)
|
2017-01-20 |
2019-11-27 |
Novartis AG |
Combination therapy for the treatment of cancer
|
|
US20200237874A1
(en)
|
2017-01-20 |
2020-07-30 |
Novartis Ag |
Combination therapy for the treatment of cancer
|
|
AU2018227583B2
(en)
|
2017-03-03 |
2023-06-01 |
Obsidian Therapeutics, Inc. |
CD19 compositions and methods for immunotherapy
|
|
KR102625293B1
(ko)
*
|
2017-03-06 |
2024-01-15 |
알토 바이오사이언스 엘엘씨 |
Il-12 및 il-18로의 il-15-기반 융합
|
|
KR20240005989A
(ko)
|
2017-03-15 |
2024-01-12 |
큐 바이오파마, 인크. |
면역 반응을 조절하는 방법
|
|
CN117363636A
(zh)
|
2017-03-27 |
2024-01-09 |
新加坡国立大学 |
一种编码嵌合受体的多核苷酸
|
|
MX2019011570A
(es)
|
2017-03-27 |
2019-11-18 |
Nat Univ Singapore |
Lineas celulares estimuladoras para expansion y activacion ex vivo de celulas asesinas naturales.
|
|
US20190048055A1
(en)
*
|
2017-03-31 |
2019-02-14 |
Altor Bioscience Corporation |
Alt-803 in combination with anti-cd38 antibody for cancer therapies
|
|
JOP20190256A1
(ar)
|
2017-05-12 |
2019-10-28 |
Icahn School Med Mount Sinai |
فيروسات داء نيوكاسل واستخداماتها
|
|
WO2018229706A1
(en)
|
2017-06-16 |
2018-12-20 |
Novartis Ag |
Combination therapy for the treatment of cancer
|
|
CA3066465A1
(en)
|
2017-06-20 |
2018-12-27 |
Nantkwest, Inc. |
Nk-92 cells and il-15 agonist combination therapy
|
|
CN118853581A
(zh)
|
2017-06-21 |
2024-10-29 |
美商生物细胞基因治疗有限公司 |
嵌合抗原受体(CARs)、组合物及其使用方法
|
|
AU2018291497A1
(en)
|
2017-06-30 |
2020-01-16 |
Xencor, Inc. |
Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15Ra and antigen binding domains
|
|
US20200306301A1
(en)
*
|
2017-07-03 |
2020-10-01 |
Torque Therapeutics, Inc. |
Polynucleotides Encoding Immunostimulatory Fusion Molecules and Uses Thereof
|
|
US11273205B2
(en)
|
2017-07-25 |
2022-03-15 |
Jiangsu Hengrui Medicine Co., Ltd. |
IL-15 protein complex pharmaceutical composition
|
|
JP2020533971A
(ja)
|
2017-08-28 |
2020-11-26 |
アルター・バイオサイエンス・コーポレーション |
Ｉｌ−１５をベースとするｉｌ−７及びｉｌ−２１への融合物
|
|
CA3074826A1
(en)
|
2017-09-05 |
2019-03-14 |
Torque Therapeutics, Inc. |
Therapeutic protein compositions and methods of making and using the same
|
|
US11905528B2
(en)
|
2017-10-12 |
2024-02-20 |
Icell Gene Therapeutics Inc. |
Compound chimeric antigen receptor (cCAR) targeting multiple antigens, compositions and methods of use thereof
|
|
CN109705211B
(zh)
|
2017-10-26 |
2020-08-18 |
苏州复融生物技术有限公司 |
一种IgG1 Fc单体及其应用
|
|
WO2019108065A1
(en)
|
2017-12-01 |
2019-06-06 |
Merus N.V. |
Use of bispecific antibody and il-15 for combination therapy
|
|
JP7386161B2
(ja)
*
|
2017-12-19 |
2023-11-24 |
ブレイズ バイオサイエンス， インコーポレイテッド |
腫瘍ホーミング及び細胞透過性ペプチド免疫抗がん剤複合体、ならびにそれらの使用方法
|
|
US11413050B2
(en)
|
2018-01-05 |
2022-08-16 |
Theragi, LLC |
Surgical clip and deployment system
|
|
WO2019139896A1
(en)
|
2018-01-09 |
2019-07-18 |
Cue Biopharma, Inc. |
Multimeric t-cell modulatory polypeptides and methods of use thereof
|
|
AU2019213843A1
(en)
|
2018-02-02 |
2020-08-20 |
Aduro Biotech Inc. |
Combination of STING agonist and IL-15/IL15-Ra for the treatment of cancer
|
|
JP7360174B2
(ja)
|
2018-02-09 |
2023-10-12 |
ナショナル ユニヴァーシティー オブ シンガポール |
ナチュラルキラー細胞免疫療法における活性化キメラ受容体及びその使用
|
|
AU2019224159B2
(en)
*
|
2018-02-26 |
2025-05-29 |
Sanofi |
IL-15 conjugates and uses thereof
|
|
MX387358B
(es)
|
2018-02-28 |
2025-03-18 |
Pfizer |
Variantes de il-15 y usos de las mismas
|
|
US11168138B2
(en)
|
2018-03-26 |
2021-11-09 |
Altor Bioscience, Llc |
Anti-PDL1, IL-15 and TGF-beta receptor combination molecules
|
|
US12441787B2
(en)
|
2018-04-02 |
2025-10-14 |
National University Of Singapore |
Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells
|
|
US11267866B2
(en)
|
2018-04-04 |
2022-03-08 |
Nant Holdings Ip, Llc |
Immunoglobulin complex comprising interleukin-15
|
|
WO2019204646A1
(en)
*
|
2018-04-18 |
2019-10-24 |
Xencor, Inc. |
Lag-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and lag-3 antigen binding domains
|
|
CA3097593A1
(en)
|
2018-04-18 |
2019-10-24 |
Xencor, Inc. |
Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
|
|
CA3097625A1
(en)
|
2018-04-18 |
2019-10-24 |
Xencor, Inc. |
Il-15/il-15ra heterodimeric fc fusion proteins and uses thereof
|
|
KR20210003814A
(ko)
|
2018-04-18 |
2021-01-12 |
젠코어 인코포레이티드 |
IL-15/IL-15Rα Fc-융합 단백질 및 TIM-3 항원 결합 도메인을 함유하는 TIM-3 표적화 이종이량체 융합 단백질
|
|
WO2019207041A1
(en)
*
|
2018-04-26 |
2019-10-31 |
F. Hoffmann-La Roche Ag |
Method of and system for tracking an animal in a population of animals
|
|
CN110437339B
(zh)
|
2018-05-04 |
2021-08-13 |
免疫靶向有限公司 |
一种以白介素15为活性成分的融合蛋白型药物前体
|
|
US20220403001A1
(en)
|
2018-06-12 |
2022-12-22 |
Obsidian Therapeutics, Inc. |
Pde5 derived regulatory constructs and methods of use in immunotherapy
|
|
CN112368298A
(zh)
*
|
2018-06-22 |
2021-02-12 |
凯德药业股份有限公司 |
嵌合跨膜蛋白及其用途
|
|
MX2020014290A
(es)
|
2018-06-22 |
2021-08-05 |
Cugene Inc |
Farmacos bioactivables a base de citoquinas y métodos de usos de los mismos.
|
|
CN121086085A
(zh)
*
|
2018-06-22 |
2025-12-09 |
科优基因公司 |
新型白介素-15 (il-15)融合蛋白及其用途
|
|
WO2020023713A1
(en)
*
|
2018-07-26 |
2020-01-30 |
Nantbio, Inc. |
Tri-cytokine txm compositions and methods
|
|
JP2021532796A
(ja)
|
2018-07-30 |
2021-12-02 |
晋宇 張 |
タンパク質ヘテロ二量体およびその使用
|
|
US12350316B2
(en)
|
2018-08-16 |
2025-07-08 |
Nantbio, Inc. |
IL7-IL 15 TxM compositions and methods
|
|
EP3837277A4
(en)
|
2018-08-17 |
2022-05-11 |
Icahn School of Medicine at Mount Sinai |
RECOMBINANT NEWCASTLE DISEASE VIRUSES AND THEIR USES IN THE PREVENTION OF RSV DISEASE OR HUMAN METAPNEUMOVIRUS INFECTION
|
|
WO2020044239A1
(en)
|
2018-08-29 |
2020-03-05 |
National University Of Singapore |
A method to specifically stimulate survival and expansion of genetically-modified immune cells
|
|
CN112996805A
(zh)
*
|
2018-08-30 |
2021-06-18 |
Hcw生物科技公司 |
多链嵌合多肽和其用途
|
|
WO2020047333A1
(en)
|
2018-08-30 |
2020-03-05 |
HCW Biologics, Inc. |
Single-chain chimeric polypeptides and uses thereof
|
|
CA3109139A1
(en)
*
|
2018-08-30 |
2020-03-05 |
HCW Biologics, Inc. |
Methods of treating aging-related disorders
|
|
CN113286812B
(zh)
|
2018-09-27 |
2025-05-30 |
西里欧发展公司 |
掩蔽型细胞因子多肽
|
|
WO2020077180A1
(en)
*
|
2018-10-11 |
2020-04-16 |
Nantcell, Inc. |
Treatment of immunosuppressed subjects
|
|
CA3116188A1
(en)
|
2018-10-12 |
2020-04-16 |
Xencor, Inc. |
Pd-1 targeted il-15/il-15ralpha fc fusion proteins and uses in combination therapies thereof
|
|
CN112912400B
(zh)
|
2018-10-19 |
2025-05-30 |
明尼苏达大学董事会 |
Nk接合子分子及其使用方法
|
|
US12466892B2
(en)
|
2018-11-08 |
2025-11-11 |
The Regents Of The University Of California |
Systems and methods for targeting cancer cells
|
|
CN113226340A
(zh)
|
2018-11-26 |
2021-08-06 |
恩卡尔塔公司 |
同时扩增多种免疫细胞类型的方法、相关组合物及其在癌症免疫疗法中的用途
|
|
CN112969718A
(zh)
|
2018-12-13 |
2021-06-15 |
江苏恒瑞医药股份有限公司 |
Il-15蛋白复合物联合pd-l1抗体用于治疗肿瘤疾病的用途
|
|
US11618776B2
(en)
|
2018-12-20 |
2023-04-04 |
Xencor, Inc. |
Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15RA and NKG2D antigen binding domains
|
|
CN113366018A
(zh)
|
2018-12-20 |
2021-09-07 |
美勒斯公司 |
用于治疗疾病的CLEC12AxCD3双特异性抗体和方法
|
|
US12497435B2
(en)
|
2019-01-11 |
2025-12-16 |
Memorial Sloan Kettering Cancer Center |
Multimerization of IL-15/IL-15R-alpha-fc complexes to enhance immunotherapy
|
|
WO2020150364A1
(en)
*
|
2019-01-15 |
2020-07-23 |
Altor Bioscience, Llc |
Human immunodeficiency virus-specific t cell receptors
|
|
KR20210137085A
(ko)
|
2019-03-05 |
2021-11-17 |
엔카르타, 인크. |
Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도
|
|
WO2020231855A1
(en)
|
2019-05-10 |
2020-11-19 |
Nant Holdings Ip, Llc |
Nogapendekin alfa-inbakicept for immune stimulant therapies and treatment of viral infections
|
|
US12085571B2
(en)
|
2019-06-13 |
2024-09-10 |
Immunitybio, Inc. |
Biological deposit labeling and tracking including isotope, rare earth metal or mitochondria tags
|
|
AU2020294797B2
(en)
|
2019-06-21 |
2025-12-18 |
Immunitybio, Inc. |
Multi-chain chimeric polypeptides and uses thereof
|
|
CN113166726A
(zh)
|
2019-07-08 |
2021-07-23 |
南克维斯特公司 |
单核细胞源性nk细胞
|
|
US11453862B2
(en)
|
2019-07-08 |
2022-09-27 |
Immunitybio, Inc. |
Mononuclear cell derived NK cells
|
|
US11364291B1
(en)
|
2019-07-18 |
2022-06-21 |
Nantcell, Inc. |
Bacillus Calmette-Guerin (BCG) and antigen presenting cells for treatment of bladder cancer
|
|
CN110478474B
(zh)
*
|
2019-08-21 |
2020-06-02 |
启辰生生物科技(珠海)有限公司 |
免疫调节剂、疫苗、细胞及应用
|
|
WO2021041886A1
(en)
*
|
2019-08-29 |
2021-03-04 |
Nantbio, Inc. |
Modified n-810 and methods therefor
|
|
US20230092895A1
(en)
|
2019-08-30 |
2023-03-23 |
Obsidian Therapeutics, Inc. |
Tandem cd19 car-based compositions and methods for immunotherapy
|
|
RU2753282C2
(ru)
*
|
2019-09-19 |
2021-08-12 |
Закрытое Акционерное Общество "Биокад" |
ИММУНОЦИТОКИН, ВКЛЮЧАЮЩИЙ ГЕТЕРОДИМЕРНЫЙ БЕЛКОВЫЙ КОМПЛЕКС НА ОСНОВЕ IL-15/IL-15Rα, И ЕГО ПРИМЕНЕНИЕ
|
|
TW202128757A
(zh)
|
2019-10-11 |
2021-08-01 |
美商建南德克公司 |
具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白
|
|
WO2021113577A1
(en)
*
|
2019-12-05 |
2021-06-10 |
Immune Targeting Inc. |
Interleukin 15 fusion proteins and prodrugs, and compositions and methods thereof
|
|
CN113135996A
(zh)
*
|
2019-12-09 |
2021-07-20 |
启愈生物技术(上海)有限公司 |
一种双特异抗体及其应用
|
|
JP7437511B2
(ja)
*
|
2019-12-31 |
2024-02-22 |
ナヴロジェン インコーポレイテッド |
腫瘍免疫抑制因子に不応性の操作されたモノクローナル抗体の組成物及び使用
|
|
AU2021205416B2
(en)
|
2020-01-08 |
2026-08-06 |
Obsidian Therapeutics, Inc. |
Compositions and methods for tunable regulation of transcription
|
|
WO2021142476A1
(en)
*
|
2020-01-12 |
2021-07-15 |
Dragonfly Therapeutics, Inc. |
Single-chain polypeptides
|
|
EP4097043A4
(en)
*
|
2020-01-31 |
2024-05-22 |
Auragent Bioscience, LLC |
ULTRABRIGHT FLUORESCENT NANOCOMPOSITE STRUCTURES FOR IMPROVED FLUORESCENT BIOASSAYS
|
|
AU2021215893A1
(en)
*
|
2020-02-05 |
2022-08-25 |
Novartis Ag |
CHO cell expressing IL-15 heterodimers
|
|
CA3169243A1
(en)
|
2020-02-11 |
2021-08-19 |
HCW Biologics, Inc. |
Methods of activating regulatory t cells
|
|
WO2021163299A1
(en)
|
2020-02-11 |
2021-08-19 |
HCW Biologics, Inc. |
Chromatography resin and uses thereof
|
|
CN116670163A
(zh)
|
2020-02-11 |
2023-08-29 |
Hcw生物科技公司 |
治疗年龄相关疾病和炎性疾病的方法
|
|
CN115244077B
(zh)
|
2020-03-11 |
2025-04-29 |
南特细胞公司 |
蛋白质治疗剂
|
|
US20230226202A1
(en)
*
|
2020-03-30 |
2023-07-20 |
Proviva Therapeutics (Hong Kong) Limited |
Il-2/il15 compositions and methods of use thereof
|
|
EP3888589A1
(en)
|
2020-04-01 |
2021-10-06 |
Koninklijke Philips N.V. |
Interdental space detection
|
|
AU2021260989A1
(en)
|
2020-04-22 |
2022-11-17 |
Novartis Ag |
Pharmaceutical compositions and pharmaceutical products of heterodimeric human interleukin-15 (hetIL-15)
|
|
AU2021262794B2
(en)
|
2020-04-29 |
2026-06-18 |
Immunitybio, Inc. |
Anti-CD26 proteins and uses thereof
|
|
IL296209A
(en)
|
2020-05-12 |
2022-11-01 |
Cue Biopharma Inc |
Multimeric t-cell modulatory polypeptides and methods of using them
|
|
US11318189B1
(en)
|
2020-05-13 |
2022-05-03 |
Nantcell, Inc. |
IL-15 agonist drug combinations for immune therapy
|
|
US12024545B2
(en)
|
2020-06-01 |
2024-07-02 |
HCW Biologics, Inc. |
Methods of treating aging-related disorders
|
|
US20230226203A1
(en)
*
|
2020-06-18 |
2023-07-20 |
Proviva Therapeutics (Hong Kong) Limited |
Activatable procytokines
|
|
CN116194471A
(zh)
*
|
2020-06-23 |
2023-05-30 |
卡德门企业有限公司 |
抗pd-1抗体和融合蛋白
|
|
CN116348483A
(zh)
|
2020-07-31 |
2023-06-27 |
南特生物公司 |
嵌合t细胞受体，核酸及其制造和使用方法
|
|
KR20250140647A
(ko)
*
|
2020-08-03 |
2025-09-25 |
난트셀, 인크. |
Il-15 초작용제에 대한 약물-특이적 약동학 검정
|
|
JP2023541366A
(ja)
|
2020-09-09 |
2023-10-02 |
キュー バイオファーマ， インコーポレイテッド |
１型真性糖尿病（ｔ１ｄ）を治療するためのｍｈｃクラスｉｉ ｔ細胞調節多量体ポリペプチド及びその使用方法
|
|
KR20230104866A
(ko)
*
|
2020-09-16 |
2023-07-11 |
베이진 엘티디 |
인터류킨 15 작제물 및 사용 방법
|
|
EP4251187A4
(en)
|
2020-11-25 |
2025-09-10 |
Xilio Dev Inc |
TUMOR-SPECIFIC CLASSIBLE LINKERS
|
|
US11459372B2
(en)
|
2020-11-30 |
2022-10-04 |
Crispr Therapeutics Ag |
Gene-edited natural killer cells
|
|
IL303269A
(en)
|
2020-12-03 |
2023-07-01 |
Century Therapeutics Inc |
Genetically engineered cells and uses thereof
|
|
US11661459B2
(en)
|
2020-12-03 |
2023-05-30 |
Century Therapeutics, Inc. |
Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
|
|
TW202241935A
(zh)
|
2020-12-18 |
2022-11-01 |
美商世紀治療股份有限公司 |
具有可調適受體專一性之嵌合抗原受體系統
|
|
AU2021410788A1
(en)
*
|
2020-12-23 |
2023-08-03 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
|
EP4271798A1
(en)
|
2020-12-30 |
2023-11-08 |
CRISPR Therapeutics AG |
Compositions and methods for differentiating stem cells into nk cells
|
|
CN113321736B
(zh)
*
|
2020-12-30 |
2024-01-09 |
苏州复融生物技术有限公司 |
一种长效化白介素15融合蛋白及其制备方法和应用
|
|
CA3206549A1
(en)
|
2021-01-29 |
2022-08-04 |
Frederick G. Vogt |
Methods of making modified tumor infiltrating lymphocytes and their use in adoptive cell therapy
|
|
WO2022204267A1
(en)
|
2021-03-24 |
2022-09-29 |
Alkermes, Inc. |
Upar antibodies and fusion proteins with the same
|
|
CA3213751A1
(en)
*
|
2021-03-31 |
2022-10-06 |
Ziyang Zhong |
Fusion proteins, pharmaceutical compositions, and therapeutic applications
|
|
US20250197525A1
(en)
|
2021-04-28 |
2025-06-19 |
Minotaur Therapeutics, Inc. |
Humanized chimeric bovine antibodies and methods of use
|
|
CN116375888A
(zh)
*
|
2021-05-08 |
2023-07-04 |
上海交通大学 |
一种融合蛋白及其制备方法和用途
|
|
EP4346875A4
(en)
*
|
2021-05-28 |
2025-04-16 |
Akso Biopharmaceutical, Inc. |
BISPECIFIC FC FUSION PROTEINS WITH SPD-1 AND IL-15
|
|
EP4351320A1
(en)
|
2021-06-09 |
2024-04-17 |
ImmunityBio, Inc. |
Methods and systems for producing a protein of interest in a plant
|
|
CN113736810B
(zh)
*
|
2021-09-08 |
2024-05-24 |
苏州因特药物研发有限公司 |
构建体、载体、蛋白、细胞、制备方法、产品及应用
|
|
WO2023081163A1
(en)
|
2021-11-02 |
2023-05-11 |
Immunitybio, Inc. |
Natural killer cells for chordoma therapy
|
|
US20230151095A1
(en)
|
2021-11-12 |
2023-05-18 |
Xencor, Inc. |
Bispecific antibodies that bind to b7h3 and nkg2d
|
|
US12297247B2
(en)
|
2022-01-22 |
2025-05-13 |
Nantcell, Inc. |
Fusion molecules of CTLA4 and IL-15
|
|
US12594323B2
(en)
|
2022-04-13 |
2026-04-07 |
Immunitybio, Inc. |
Methods of reducing neuroinflammation
|
|
CN116854821A
(zh)
|
2022-08-15 |
2023-10-10 |
海徕科(北京)生物技术有限公司 |
IL-15突变体-Fc/IL-15Rα亚基-Fc异源二聚体及其用途
|
|
EP4335870A1
(en)
|
2022-09-06 |
2024-03-13 |
NantCell, Inc. |
Peptide therapeutics against sars-cov-2 spike protein
|
|
WO2024102636A1
(en)
|
2022-11-07 |
2024-05-16 |
Xencor, Inc. |
Bispecific antibodies that bind to b7h3 and mica/b
|
|
WO2024118836A1
(en)
|
2022-11-30 |
2024-06-06 |
Iovance Biotherapeutics, Inc. |
Processes for production of tumor infiltrating lymphocytes with shortened rep step
|
|
CN120916753A
(zh)
*
|
2023-03-29 |
2025-11-07 |
星锐医药(苏州)有限公司 |
编码治疗性多肽的核酸及包含所述核酸的脂质纳米颗粒组合物
|
|
US20240327484A1
(en)
*
|
2023-03-31 |
2024-10-03 |
Immunitybio, Inc. |
Il-12/il-18 superkines
|
|
CN121240886A
(zh)
*
|
2023-06-06 |
2025-12-30 |
杰科生物医药公司 |
白细胞介素-15融合蛋白及其使用方法
|
|
EP4739334A1
(en)
|
2023-07-05 |
2026-05-13 |
Nanotein Technologies, Inc. |
Cell signaling complexes and uses thereof
|
|
IL325907A
(en)
|
2023-07-13 |
2026-03-01 |
Iovance Biotherapeutics Inc |
Cytokine encoding lentiviral vectors and uses thereof for making tumor infiltrating lymphocytes
|
|
US12473529B2
(en)
|
2023-07-18 |
2025-11-18 |
Nanotein Technologies, Inc. |
Reagents, reagent kits, and culture media for activating and expanding immune cells and uses thereof
|
|
WO2025076124A1
(en)
*
|
2023-10-02 |
2025-04-10 |
Immunitybio, Inc. |
Methods of generating, stimulating, or increasing proliferation of different subsets of cd8+ t cells
|
|
WO2025085672A1
(en)
|
2023-10-17 |
2025-04-24 |
Xencor, Inc. |
Bispecific antibodies that bind to nkp46 and mica/b
|
|
CN122094703A
(zh)
*
|
2023-10-31 |
2026-05-26 |
免疫生物公司 |
多链嵌合多肽及其在治疗晚期实体瘤中的用途
|
|
WO2025151752A1
(en)
|
2024-01-10 |
2025-07-17 |
Xilio Development, Inc. |
Masked il-2 cytokines and methods of use thereof
|
|
CN118108809B
(zh)
*
|
2024-03-15 |
2025-02-28 |
西湖实验室(生命科学和生物医学浙江省实验室) |
一种跨膜荧光蛋白、水溶荧光蛋白及其用途
|
|
WO2026006784A1
(en)
|
2024-06-28 |
2026-01-02 |
Iovance Biotherapeutics, Inc. |
Methods of making tumor reactive peripheral blood lymphocytes (trpbl)
|
|
US20260001951A1
(en)
|
2024-06-28 |
2026-01-01 |
Immunitybio, Inc. |
Anti-SLAMF7 Antibodies And Therapeutics
|
|
US20260027155A1
(en)
|
2024-07-23 |
2026-01-29 |
Immunitybio, Inc. |
Compositions and methods related to potent cytotoxic m-cenk cells from cd3/cd14-depleted apheresis products
|